Dr. Reddy’s forays into India’s biosimilar immuno-oncology market, launches Nivorz
In 2025, the immuno-oncology market in India was estimated to be around ₹3,900 crore and predominantly driven by checkpoint inhibitors such as nivolumab, pembrolizumab and toripalimab.
· 9/15/2026, 4:03:59 PM· 2 min read
In 2025, the immuno-oncology market in India was estimated to be around ₹3,900 crore and predominantly driven by checkpoint inhibitors such as nivolumab, pembrolizumab and toripalimab.
Read original story →Related stories
business
MDL signs MoU as Anchor Shipyard for Greenfield Shipbuilding Industrial Cluster at Dighi
business
RBI files caveat after rejecting Tata Sons bid to avoid listing, source says
business
Amazon Now crosses $1 billion annualised sales in India in 3 months
business